Equillium Inc. Expands Financial Strategy with Cryptocurrency Treasury Reserve Integration

Reuters

2025/08/04

<a href="https://laohu8.com/S/EQ">Equillium Inc.</a> Expands Financial <a href="https://laohu8.com/S/MSTR">Strategy</a> with Cryptocurrency Treasury Reserve Integration

Equillium Inc., a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced an expansion of its financial strategy to include a cryptocurrency treasury reserve. This move aims to diversify its assets, enhance liquidity, and potentially increase long-term capital appreciation. CEO Bruce Steel stated that following a comprehensive assessment, the board has determined this strategy aligns with stockholders' interests. The company plans to provide further updates on the strategy by the third quarter of 2025. Concurrently, Equillium remains committed to advancing its biotech mission, particularly the clinical development of EQ504, its aryl hydrocarbon receptor modulator. As of mid-2025, the company reported having $11.5 million in cash and expects to be funded into the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250804543878) on August 04, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556638118"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556638118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556638118?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556638118","market":"fut","top_or_hot":-1,"title":"Equillium Inc. Expands Financial Strategy with Cryptocurrency Treasury Reserve Integration","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EQ\">Equillium Inc.</a> Expands Financial <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> with Cryptocurrency Treasury Reserve Integration\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Equillium Inc., a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced an expansion of its financial strategy to include a cryptocurrency treasury reserve. This move aims to diversify its assets, enhance liquidity, and potentially increase long-term capital appreciation. CEO Bruce Steel stated that following a comprehensive assessment, the board has determined this strategy aligns with stockholders' interests. The company plans to provide further updates on the strategy by the third quarter of 2025. Concurrently, Equillium remains committed to advancing its biotech mission, particularly the clinical development of EQ504, its aryl hydrocarbon receptor modulator. As of mid-2025, the company reported having $11.5 million in cash and expects to be funded into the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250804543878) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Equillium Inc. Expands Financial Strategy with Cryptocurrency Treasury Reserve Integration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEquillium Inc. Expands Financial Strategy with Cryptocurrency Treasury Reserve Integration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-04 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EQ\">Equillium Inc.</a> Expands Financial <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> with Cryptocurrency Treasury Reserve Integration\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Equillium Inc., a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced an expansion of its financial strategy to include a cryptocurrency treasury reserve. This move aims to diversify its assets, enhance liquidity, and potentially increase long-term capital appreciation. CEO Bruce Steel stated that following a comprehensive assessment, the board has determined this strategy aligns with stockholders' interests. The company plans to provide further updates on the strategy by the third quarter of 2025. Concurrently, Equillium remains committed to advancing its biotech mission, particularly the clinical development of EQ504, its aryl hydrocarbon receptor modulator. As of mid-2025, the company reported having $11.5 million in cash and expects to be funded into the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250804543878) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL2KNZgy:1","article_id":"2556638118","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556638118","pubTimestamp":1754310637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Equillium Inc., a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced an expansion of its financial strategy to include a cryptocurrency treasury reserve. This move aims to diversify its assets, enhance liquidity, and potentially increase long-term capital appreciation. CEO Bruce Steel stated that following a comprehensive assessment, the board has determined this strategy aligns with stockholders' interests. The company plans to provide further updates on the strategy by the third quarter of 2025. Concurrently, Equillium remains committed to advancing its biotech mission, particularly the clinical development of EQ504, its aryl hydrocarbon receptor modulator. As of mid-2025, the company reported having $11.5 million in cash and expects to be funded into the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","EQ":"Equillium Inc.","BK4139":"生物科技"},"translate_title":"Equillium Inc.通过加密货币国库储备整合扩展财务战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQ":0.9},"content_text":"Equillium Inc. Expands Financial Strategy with Cryptocurrency Treasury Reserve Integration\n    \n\n        Equillium Inc., a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced an expansion of its financial strategy to include a cryptocurrency treasury reserve. This move aims to diversify its assets, enhance liquidity, and potentially increase long-term capital appreciation. CEO Bruce Steel stated that following a comprehensive assessment, the board has determined this strategy aligns with stockholders' interests. The company plans to provide further updates on the strategy by the third quarter of 2025. Concurrently, Equillium remains committed to advancing its biotech mission, particularly the clinical development of EQ504, its aryl hydrocarbon receptor modulator. As of mid-2025, the company reported having $11.5 million in cash and expects to be funded into the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250804543878) on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}